Skip to main content

Table 1 Clinical characteristics of the study population between the genotype groups

From: Effects of GRK5 and ADRB1 polymorphisms influence on systolic heart failure

Characteristic

GRK5 Gln41Gln (n = 1681)

GRK5 Gln41Leu (n = 26)

P value

ADRB1 Arg389Arg (n = 907)

ADRB1 Arg389Gly (n = 749)

ADRB1 Arg389Gly (n = 129)

P value

Age, yrs

58.70 ± 11.34

59.12 ± 9.62

0.852

58.71 ± 11.20

58.84 ± 11.38

56.61 ± 11.99

0.114

Male gender, %

35.7

50.0

0.131

37.2

34.7

47.3

0.023

Weight, kg

62.78 ± 11.04

66.24 ± 8.93

0.119

63.12 ± 10.84

62.60 ± 11.59

63.50 ± 9.76

0.528

Height, cm

161.24 ± 7.92

161.50 ± 8.56

0.868

161.77 ± 7.75

160.82 ± 7.92

163.35 ± 8.27

0.001

Systolic BP, mmHg

133.36 ± 22.43

137.88 ± 17.93

0.316

133.56 ± 23.67

132.95 ± 20.41

132.04 ± 21.14

0.711

Diastolic BP, mmHg

75.71 ± 11.79

79.04 ± 10.96

0.161

75.89 ± 11.83

75.51 ± 11.64

74.75 ± 11.09

0.543

Heart rate, beats/min

74.45 ± 11.38

79.29 ± 12.51

0.039

74.00 ± 10.53

75.06 ± 11.42

71.28 ± 13.90

0.002

Smoking, %

23.6

30.8

0.393

23.7

22.1

29.2

0.199

Drinking, %

14.2

19.2

0.467

13.7

14.2

20.8

0.099

Hypertension, %

39.4

53.8

0.136

38.8

39.9

35.4

0.614

CAD, %

9.3

7.7

0.776

9.5

9.0

5.0

0.470

Diabetes mellitus, %

11.5

15.4

0.542

11.9

11.0

8.5

0.496

SHF, %

13.8

15.4

0.817

13.3

13.9

10.0

0.490

Medication, n (%)

       

 ACE inhibitors

62 (3.7)

2 (7.7)

0.254

35 (3.8)

22 (2.9)

8 (6.2)

0.174

 Angiotensin receptor blockers

156 (9.3)

3 (11.5)

0.729

69 (7.6)

69 (9.2)

12 (8.0)

0.456

 Beta-blockers

122 (7.3)

5 (19.2)

0.039

58 (6.4)

61 (8.1)

5 (3.8)

0.132

 Aldosterone antagonists

142 (8.4)

2 (7.7)

1.000

69 (7.6)

67 (9.0)

9 (6.9)

0.520

 Diuretics

176 (10.5)

2 (7.7)

1.000

89 (9.8)

79 (10.6)

12 (9.2)

0.825

 Digoxin

60 (3.6)

0

1.000

36 (4.0)

20 (2.7)

4 (3.1)

0.347

Echocardiography

       

 LAD, mm

35.58 ± 6.78

34.58 ± 4.21

0.474

35.63 ± 7.09

35.37 ± 6.32

35.84 ± 5.89

0.660

 LVESD, mm

30.68 ± 7.41

29.54 ± 3.32

0.451

30.75 ± 7.78

30.25 ± 6.76

30.77 ± 6.60

0.383

 LVEDD, mm

47.61 ± 6.40

47.29 ± 4.56

0.805

47.86 ± 6.62

47.39 ± 6.02

48.47 ± 5.66

0.126

 LVEF, %

61.51 ± 9.46

62.68 ± 7.40

0.540

61.80 ± 9.37

61.64 ± 9.22

61.62 ± 10.22

0.941

Laboratory

       

 Total cholesterol, mmol/l

5.02 ± 1.15

4.73 ± 1.21

0.198

5.00 ± 1.09

5.04 ± 1.23

4.84 ± 1.05

0.172

 LDL-C, mmol/l

3.03 ± 1.10

2.90 ± 0.88

0.539

3.04 ± 1.06

3.02 ± 0.90

2.85 ± 0.74

0.190

 HDL-C, mmol/l

1.29 ± 0.34

1.19 ± 0.31

0.127

1.27 ± 0.35

1.31 ± 0.34

1.26 ± 0.32

0.351

 Triglyceride, mmol/l

1.41 [1.00, 2.01]

1.64 [1.67, 2.19]

0.838

1.40[0.99, 2.00]

1.39 [1.01, 2.00]

1.41 [1.00, 2.01]

0.988

 Glycosylated hemoglobin, %

5.80 [5.50, 6.20]

5.70 [5.38, 6.25]

0.623

5.70 [5.50, 6.20]

5.80 [5.50, 6.20]

5.64 [5.40, 6.00]

0.041

 Creatinine, umol/l

73.46 ± 25.31

78.20 ± 15.35

0.351

73.20 ± 22.38

74.12 ± 28.14

72.54 ± 21.80

0.678

 eGFR, ml/min/1.73 m2

97.56

86.26

0.078

98.38

96.47

99.47

0.209

 Median (Q1,Q3)

[83.59, 113.45]

[76.26, 112.03]

 

[83.13, 113.22]

[82.18, 113.32]

[86.83, 119.79]

 

 Plasma NT-proBNP, pg/ml

52.00

45.00

0.867

53.00

51.00

55.00

0.926

 Median (Q1,Q3)

[30.00, 87.00]

[33.00, 102.00]

 

[30.00, 87.00]

[29.00, 91.00]

[28.00, 103.00]

 
  1. Note: ACE inhibitor, angiotensin converting enzyme inhibitor; BP, blood pressure; CAD, coronary artery disease; eGFR, glomerular filtration rate (ml/min/1.73 m2) = 175 × creatinine-1.234 × age-0.179 × 0.79 (if female); HDL-C, high-density lipoprotein cholesterol; LAD, Left atrial diameter; LDL-C, low-density lipoprotein cholesterol; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic dimension; LVEDD, left ventricular end-diastolic dimension; NT-ProBNP, N-terminal pro-B-type natriuretic peptide; SHF, systolic heart failure.
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us